Protein marker for chronic hepatitis liver fibrosis and detection method thereof

Abstract

The invention belongs to the field of biomedicine, and relates to a non-traumatic serum protein molecular marker for diagnosing chronic hepatitis liver fibrosis. The protein marker provided by the invention is one or more of the following proteins: human serum glycosylation apoferritin-transferrin A chain, glycoprotein HC composite structure C chain, human complement component C3c, immune globulin MFc segment, human hemoglobin beta chain variant HbS wake, or protein A mimetic peptide tree-like ligand of IgG1Fc segment A chain (Herceptin). The invention also provides the detection method and application of the serum protein marker and a kit prepared according to the serum protein marker. In the invention, the serum protein molecular marker and related indexes such as mRNA and MicroRNA can be used for predicting the degree of chronic hepatitis liver fibrosis and can be used for prognosis judgment, treatment selection and curative effect evaluation.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

AI Technical Summary

Benefits of technology

This patented technology helps diagnose or treat patients with cirrhosis by measuring their levels of blood proteins called albumen concentrations during disease activity over time. By comparing these measurements against previous data from healthy individuals we found out which factors were associated more strongly than others when compared between them. These results showed how well they could identify people who are at risk of developing this condition early on before symptoms appear.

Problems solved by technology

This patents discusses different types of tests or techniques being developed over several decades ago but they all lack accuracy when it comes back from testing new samples without any evidence showing significant differences between them due to factors like age difference, gene mutations, environmental influences during disease development, etc., making accurate assessment difficult even if some were available. Therefore, this problem needs to be solved through novel approaches involving target identification and quantitative measurement instead of traditional histopatholog analysis.

Images